Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (1993)	10/2/1997 8:17:00 AM
From: Peter Silsbee	of 6136

A couple of points from the just-arrived annual report. On page 1, there is a graph titled "Viracept duration of response." It appears that the number of patients failing drops off significantly with time: at 12 weeks, 90-95% are responding, at 24, just under 90, at 36, maybe 87, at 48, still over 85. It is tempting (though scientifically iffy) to extrapolate from this. I might even come down in the camp that says PI resistance is not likely to approach 100% in a patient's lifetime. But I'll avoid drawing that conclusion. The other point is also probably old news, but I don't recall seeing it before: "Having revised our clinical development strategy following a mid-year meeting with FDA, we have set as our goal the preparation of a NDA covering our intravenous formulation of THYMITAQ for submission by the end of calendar 1998 or early in calendar 1999." This is about a year later than they had planned. Would anyone like to shed some light on this? PLS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next